Notice: This company has been marked as potentially delisted and may not be actively trading. Cogent Biosciences (UMRX) News Today Add Compare Share Share Headlines Stock AnalysisCompetitorsHeadlinesTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Cogent Biosciences exec buys $332K in common stockJanuary 16, 2025 | markets.businessinsider.comPiper Sandler Sticks to Its Buy Rating for Cogent Biosciences (COGT)January 15, 2025 | markets.businessinsider.comCogent Biosciences price target lowered to $14 from $17 at H.C. WainwrightJanuary 15, 2025 | markets.businessinsider.comCogent Biosciences (COGT) Gets a Buy from J.P. MorganDecember 19, 2024 | markets.businessinsider.comCogent Biosciences price target raised to $21 from $19 at JPMorganNovember 15, 2024 | markets.businessinsider.comCogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial ResultsNovember 12, 2024 | tmcnet.comPromising Developments and Financial Stability Propel Cogent Biosciences to a Buy RatingNovember 6, 2024 | markets.businessinsider.comPromising Preclinical Data and Competitive Edge Drive Buy Rating for Cogent BiosciencesNovember 4, 2024 | markets.businessinsider.comCogent Biosciences announces pipeline expansion into KRASOctober 24, 2024 | markets.businessinsider.comCogent Biosciences: Need To Wait For More Data For Adequate DifferentiationSeptember 30, 2024 | seekingalpha.comCogent Biosciences, Inc. (COGT): This Small-Cap Healthcare Stock Is A Good Buy Right NowSeptember 5, 2024 | msn.comCogent Biosciences Garners Buy Rating Amid Promising Clinical Trials and Strategic Growth PotentialAugust 7, 2024 | markets.businessinsider.comCOGT Stock Earnings: Cogent Biosciences Misses EPS for Q2 2024August 6, 2024 | investorplace.comCogent Bio spikes after updating late-stage data for lead assetMay 24, 2024 | msn.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Ardelyx (ARDX), Cogent Biosciences (COGT) and Immunocore Holdings (IMCR)May 24, 2024 | markets.businessinsider.comBuy Rating on Cogent Biosciences: Financial Stability and Promising Clinical Trials Fuel Positive OutlookMay 13, 2024 | markets.businessinsider.comAnalyst Issues Buy Rating on Cogent Biosciences Amid Clinical and Financial MilestonesMay 10, 2024 | markets.businessinsider.comCogent Biosciences EPS of -$0.62 misses by $0.11May 7, 2024 | msn.comCOGT Stock Earnings: Cogent Biosciences Misses EPS for Q1 2024May 7, 2024 | investorplace.comCogent Biosciences IncApril 24, 2024 | money.usnews.comAnalysts Conflicted on These Healthcare Names: Cogent Biosciences (COGT) and Altimmune (ALT)February 26, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Cogent Biosciences (COGT) and Moderna (MRNA)February 26, 2024 | markets.businessinsider.comCogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsFebruary 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cogent Biosciences Ahead of Key Data Presentation on Bezuclastinib with Strong Upside PotentialFebruary 15, 2024 | markets.businessinsider.comCogent Biosciences Stock Soars After $225M Private PlacementFebruary 14, 2024 | marketwatch.comCogent Biosciences announces oversubscribed $225M private placementFebruary 14, 2024 | msn.comBuy Rating on Cogent Biosciences Amid Market Overreaction and Promising Drug ProspectsFebruary 9, 2024 | markets.businessinsider.comCiti starts Cogent Biosciences at buy, cites GI tumor drug potentialFebruary 8, 2024 | msn.comBuy Rating Reiterated for Cogent Biosciences as Bezuclastinib Shows Promise in SUMMIT TrialDecember 15, 2023 | markets.businessinsider.comMaintaining Buy on Cogent Biosciences Amid Anticipation of Differentiating Data for BezuclastinibDecember 13, 2023 | markets.businessinsider.comDow Surges 100 Points; Cogent Biosciences Shares PlungeDecember 11, 2023 | markets.businessinsider.comCogent Biosciences Shares Fall Despite Positive Clinical Trial Updates For Systemic Mastocytosis TreatmentDecember 11, 2023 | markets.businessinsider.comCogent Reports Positive Data From Phase 2 APEX Trial Of Bezuclastinib In Systemic MastocytosisDecember 11, 2023 | markets.businessinsider.comCogent slumps after mid-stage data for rare disorder therapyDecember 11, 2023 | msn.comPotential Upside for Cogent Biosciences Due to Imminent Data Readout for Bezuclastinib and Underpriced SharesNovember 21, 2023 | markets.businessinsider.comPromising Clinical Trials and Strong Financial Position Justify Buy Rating for Cogent BiosciencesNovember 14, 2023 | markets.businessinsider.comPromising Clinical Trials and Strong Financial Position Support Buy Rating for Cogent BiosciencesNovember 4, 2023 | markets.businessinsider.comPromising Market Potential for Cogent Biosciences’ Bezuclastinib Spurs Buy RatingOctober 28, 2023 | markets.businessinsider.comAnalyst Expectations for Cogent Biosciences's FutureAugust 30, 2023 | benzinga.comCogent Biosciences Is Beginning To Differentiate Its KIT InhibitorAugust 15, 2023 | msn.comLifeSci Capital Remains a Buy on Cogent Biosciences (COGT)August 8, 2023 | markets.businessinsider.comDoes Cogent Biosciences, Inc. (COGT) Have the Potential to Rally 78.9% as Wall Street Analysts Expect?July 11, 2023 | msn.comCogent Biosciences Shares Rise on Fairmount Funds Management's Stake AcquisitionJune 13, 2023 | marketwatch.com9 Analysts Have This to Say About Cogent BiosciencesJune 12, 2023 | markets.businessinsider.comCogent Biosciences (COGT) Receives a Buy from LifeSci CapitalJune 5, 2023 | markets.businessinsider.comCogent Biosciences Reports Recent Business Highlights and First Quarter 2023 Financial ResultsMay 9, 2023 | technews.tmcnet.comBaird Initiates Coverage of Cogent Biosciences (COGT) with Outperform RecommendationApril 29, 2023 | msn.comAnalyst Ratings for Cogent BiosciencesApril 28, 2023 | markets.businessinsider.comNeedham Maintains Cogent Biosciences (COGT) Buy RecommendationApril 21, 2023 | msn.comExpert Ratings for Cogent BiosciencesMarch 27, 2023 | benzinga.com Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for UMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address UMRX Media Mentions By Week UMRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. UMRX News Sentiment▼0.000.62▲Average Medical News Sentiment UMRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. UMRX Articles This Week▼00▲UMRX Articles Average Week Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for UMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NRIX News XNCR News KNSA News PRAX News RCUS News DAWN News OCUL News ARVN News ANIP News SPRY News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:UMRX) was last updated on 1/24/2025 by MarketBeat.com Staff From Our PartnersVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredStunning Trump Manhattan Project Now UnderwayJust as I predicted, President Trump announced his #1 move during his first 100 days... His allies are call...Banyan Hill Publishing | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredThe Stock I’m Calling My #1 of the DecadeThe stock I reveal right here is my #1 stock of the decade. In fact, it might be my favorite stock ever. ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
